ClinicalTrials.gg
RecruitingNCT07290283Updated Oct 13, 2026

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

A Phase 1 interventional study of AZD3974 and Placebo in Healthy Participants, sponsored by AstraZeneca. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.

Read the detailed description

This is a first in human, randomized, single-blind, placebo-controlled study. It consists of two parts.

Part A (single ascending dose - SAD): This study part will enroll six cohorts (plus two optional additional cohorts) of healthy participants (Part A1), three cohorts (plus one optional additional cohort) of healthy Japanese participants (Part A2) and one cohort (plus one optional additional cohort) of healthy Chinese participants (Part A3). Cohort 3 of Part A1 will be extended to evaluate the effect of food intake on the PK of AZD3974. In Part A (all cohorts), participants will receive a single dose of AZD3974 or placebo.

Part B (Multiple Ascending Dose - MAD): This study part will consist of four cohorts (plus two optional additional cohorts) of healthy participants (Part B1) and one cohort (plus one optional additional cohort) of healthy Japanese participants (Part B2). In all Part B cohorts, participants will receive multiple doses of AZD3974 or placebo.

Both Part A and Part B will comprise of:

  • A Screening Period of maximum 28 days
  • A Dosing session during which participants will receive the study intervention at study specific time points.
  • Follow-up Period of 7 days post last-dose.
02

Conditions studied

  • Healthy Participants

Keywords

  • Single ascending dose
  • Multiple ascending dose
  • Pharmacokinetics
  • Impact of food
  • First-in-human
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female (of non-) participants with suitable veins for cannulation or repeated venipuncture at the Screening Visit.
  • All females must have a negative pregnancy test. Females of non-childbearing potential must be confirmed via status or documentation of irreversible surgical sterilization at the Screening Visit.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the methods.
  • Have a between 18 and 32 kg/m2 inclusive and weigh at least 50 kg at Screening.
  • For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female participants are to be Japanese (eg, natives of Japan or Japan Americans), defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.
  • For healthy Chinese cohort (Part A3): healthy male and female Chinese participants for whom both parents and 4 grandparents are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any abnormal laboratory values, vital signs, or any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
  • Any positive result on Screening for serum and C viruses and .
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead electrocardiography at Screening and/or admission to the Clinical Unit .
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • Positive screen for drugs of abuse, or alcohol, or cotinine.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • Participants who have previously received AZD3974.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    Part A1 (SAD) Cohort 1: AZD3974 (Dose 1)

    Healthy participants will receive a single dose of AZD3974 - Dose 1

    Drug: AZD3974

  • Experimental
    Part A1 (SAD) Cohort 2: AZD3974 (Dose 2)

    Healthy participants will receive a single dose of AZD3974 - Dose 2

    Drug: AZD3974

  • Experimental
    Part A1 (SAD) Cohort 3: AZD3974 (Dose 3) (Food Effect Cohort)

    Healthy participants will receive two single doses of AZD3974 - Dose 3

    Drug: AZD3974

  • Experimental
    Part A1 (SAD) Cohort 4: AZD3974 (Dose 4)

    Healthy participants will receive a single dose of AZD3974 - Dose 4

    Drug: AZD3974

  • Experimental
    Part A1 (SAD) Cohort 5: AZD3974 (Dose 5)

    Healthy participants will receive a single dose of AZD3974 - Dose 5

    Drug: AZD3974

  • Experimental
    Part A1 (SAD) Cohort 6: AZD3974 (Dose 6)

    Healthy participants will receive a single dose of AZD3974 - Dose 6

    Drug: AZD3974

  • Experimental
    Part A1 (SAD) optional additional Cohort 7: AZD3974

    Healthy participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Experimental
    Part A1 (SAD) optional additional Cohort 8: AZD3974

    Healthy participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Placebo comparator
    Part A1 (SAD) Cohort: Placebo

    Healthy participants will receive a single dose of matching placebo to AZD3974

    Other: Placebo

  • Placebo comparator
    Part A1 (SAD) Cohort 3: Placebo (Food Effect Cohort)

    Healthy participants will receive two single doses of matching placebo to AZD3974

    Other: Placebo

  • Experimental
    Part A2 (SAD) Japanese Cohort 1: AZD3974

    Healthy Japanese participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Experimental
    Part A2 (SAD) Japanese Cohort 2: AZD3974

    Healthy Japanese participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Experimental
    Part A2 (SAD) Japanese Cohort 3: AZD3974

    Healthy Japanese participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Experimental
    Part A2 (SAD) optional additional Japanese Cohort 4: AZD3974

    Healthy Japanese participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Placebo comparator
    Part A2 (SAD) Japanese Cohort: Placebo

    Healthy Japanese participants will receive a single dose of matching placebo to AZD3974

    Other: Placebo

  • Experimental
    Part A3 (SAD) Chinese Cohort 1: AZD3974

    Healthy Chinese participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Experimental
    Part A3 (SAD) optional additional Chinese Cohort 2: AZD3974

    Healthy Chinese participants will receive a single dose of AZD3974

    Drug: AZD3974

  • Placebo comparator
    Part A3 (SAD) Chinese Cohort: Placebo

    Healthy Chinese participants will receive a single dose of matching placebo to AZD3974

    Other: Placebo

  • Experimental
    Part B1 (MAD) Cohort 1: AZD3974

    Healthy participants will receive multiple doses of AZD3974

    Drug: AZD3974

  • Experimental
    Part B1 (MAD) Cohort 2: AZD3974

    Healthy participants will receive multiple doses of AZD3974

    Drug: AZD3974

  • Experimental
    Part B1 (MAD) Cohort 3: AZD3974

    Healthy participants will receive multiple doses of AZD3974

    Drug: AZD3974

  • Experimental
    Part B1 (MAD) Cohort 4: AZD3974

    Healthy participants will receive multiple doses of AZD3974

    Drug: AZD3974

  • Experimental
    Part B1 (MAD) optional additional Cohort 5: AZD3974

    Healthy participants will receive multiple doses of AZD3974

    Drug: AZD3974

  • Experimental
    Part B1 (MAD) optional additional Cohort 6: AZD3974

    Healthy participants will receive multiple doses of AZD3974

    Drug: AZD3974

  • Placebo comparator
    Part Bl (MAD) Cohort: Placebo

    Healthy participants will receive multiple doses of matching placebo to AZD3974

    Other: Placebo

  • Experimental
    Part B2 (MAD) Japanese Cohort 1: AZD3974

    Healthy Japanese participants will receive multiple doses of AZD397

    Drug: AZD3974

  • Experimental
    Part B2 (MAD) optional additional Japanese Cohort 2: AZD3974

    Healthy Japanese participants will receive multiple doses of matching placebo to AZD3974

    Drug: AZD3974

  • Placebo comparator
    Part B2 (MAD) Japanese Cohort: Placebo

    Healthy Japanese participants will receive multiple doses of matching placebo to AZD3974

    Other: Placebo

Interventions

  • DrugAZD3974

    AZD3974 will be administered as an oral solution.

  • OtherPlacebo

    Placebo will be administered as an oral solution.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of AZD3974 following oral administration of single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Upto Day 7; Part A1 Cohort 3: Upto Day 10; Part B: Upto Day 14

Secondary outcomes

  1. Part A and Part B: Plasma concentrations of AZD3974

    To characterize the plasma concentrations of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  2. Part A1-Cohort 3: Plasma concentrations of AZD3974

    To assess the impact of food (fed) on the single-dose plasma concentrations of AZD3974

    Time frame: Day 1 to Day 4

  3. Part A and Part B: Urine concentrations of AZD3974

    To characterize the urine concentration of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1; Part B: Day 1 and Day 7

  4. Part A1-Cohort 3: Urine concentrations of AZD3974

    To assess the impact of food (fed) on the single-dose urine concentrations of AZD3974

    Time frame: Day 1 and Day 3

  5. Part A and Part B: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  6. Part A1-Cohort 3: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  7. Part A: Area under concentration-time curve from time 0 to infinity (AUCinf)

    To characterize the PK of AZD3974 following single ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Day 1 to Day 2

  8. Part A1-Cohort 3: Area under concentration-time curve from time 0 to infinity (AUCinf)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  9. Part A and Part B: Maximum observed drug concentration (Cmax)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  10. Part A1-Cohort 3: Maximum observed drug concentration (Cmax)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  11. Part A and Part B: Time to reach maximum observed concentration (tmax)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  12. Part A1-Cohort 3: Time to reach maximum observed concentration (tmax)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  13. Part A and Part B: Terminal elimination half-life (t½λz)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  14. Part A1-Cohort 3: Terminal elimination half-life (t½λz)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  15. Part A and Part B: Apparent total body clearance (CL/F)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  16. Part A1-Cohort 3: Apparent total body clearance (CL/F)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  17. Part A and Part B: Apparent volume of distribution based on the terminal phase (Vz/F)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  18. Part A1-Cohort 3: Apparent volume of distribution based on the terminal phase (Vz/F)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  19. Part A and Part B: Individual and cumulative amount of unchanged drug excreted into urine from time t0 to time tlast [Ae(0-last)]

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1; Part B: Day 1 and Day 7

  20. Part A1-Cohort 3: Individual and cumulative amount of unchanged drug excreted into urine from time t0 to time tlast [Ae(0-last)]

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 and Day 3

  21. Part A and Part B: Individual and cumulative percentage of dose excreted unchanged in urine from time t0 to tlast [fe(0-last)]

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1; Part B: Day 1 and Day 7

  22. Part A1-Cohort 3: Individual and cumulative percentage of dose excreted unchanged in urine from time t0 to tlast [fe(0-last)]

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 and Day 3

  23. Part A and Part B: Renal clearance (CLR)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants

    Time frame: Part A: Day 1; Part B: Day 1 and Day 7

  24. Part A1-Cohort 3: Renal clearance (CLR)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 and Day 3

  25. Part A and Part B: Mean Residence Time (MRT)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  26. Part A1-Cohort 3: Mean Residence Time (MRT)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  27. Part A and Part B: Time delay between drug administration and the first observed concentration (tlag)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  28. Part A1-Cohort 3: Time delay between drug administration and the first observed concentration (tlag)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  29. Part A and Part B: Time of last quantifiable concentration (tlast)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9

  30. Part A1-Cohort 3: Time of last quantifiable concentration (tlast)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 to Day 4

  31. Part A and Part B: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1 t2)]

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1; Part B: Day 1 and Day 7

  32. Part A1-Cohort 3: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1 t2)]

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 and Day 3

  33. Part A and Part B: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 - [fe(t1-t2)]

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1; Part B: Day 1 and Day 7

  34. Part A1-Cohort 3: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 - [fe(t1-t2)]

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 and Day 3

  35. Part A and Part B: Cumulative amount of unchanged drug excreted into urine (Aeinf)

    To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.

    Time frame: Part A: Day 1; Part B : Day 1 and Day 7

  36. Part A1-Cohort 3: Cumulative amount of unchanged drug excreted into urine (Aeinf)

    To assess the impact of food (fed) on the single-dose PK of AZD3974

    Time frame: Day 1 and Day 3

  37. Part B: Area under concentration time curve in the dosing interval (AUCtau)

    To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants

    Time frame: Day 1 to Day 9

  38. Part B: Observed lowest concentration before the next dose is administered: (Ctrough)

    To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 9

  39. Part B: Accumulation ratio for AUC calculated as steady State AUCτ/First Dose AUCτ (Rac AUC)

    To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants

    Time frame: Day 1 to Day 9

  40. Part B: Accumulation ratio for Cmax calculated as steady State Cmax/First Dose Cmax (Rac Cmax)

    To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 9

  41. Part B: Temporal change parameter calculated as steady State AUCτ/First Dose AUCinf (TCP)

    To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants.

    Time frame: Day 1 to Day 9

07

Study locations

2 of 2 sites recruiting
  • Research Site
    Glendale, California 91206, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21225, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 18, 2025
StartActual
Dec 10, 2025
Primary completionEst.
Dec 8, 2026was Oct 2026
CompletionEst.
Dec 8, 2026was Oct 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 21, 2026→Dec 8, 2026
Oct 13, 2026
Study completion
Oct 21, 2026→Dec 8, 2026
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Oct 21, 2026→Dec 8, 2026
    Study completion Oct 21, 2026→Dec 8, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07290283
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Dec 10, 2025
Primary completion
Dec 8, 2026 (estimated)
Completion
Dec 8, 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion